- Home
- FLGT
as 11-21-2024 10:34am EST
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | EL MONTE |
| Market Cap: | 683.5M | IPO Year: | 2016 |
| Target Price: | $28.50 | AVG Volume (30 days): | 247.2K |
| Analyst Decision: | Hold | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.50 | EPS Growth: | N/A |
| 52 Week Low/High: | $16.61 - $30.68 | Next Earning Date: | 11-08-2024 |
| Revenue: | $277,761,000 | Revenue Growth: | -3.02% |
| Revenue Growth (this year): | -0.49% | Revenue Growth (next year): | 14.04% |
Stock Insider Trading Activity of Fulgent Genetics Inc. (FLGT)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Gao Hanlin | FLGT | Chief Scientific Officer | Sep 3 '24 | Sell | $21.96 | 1,503 | $33,007.38 | 923,057 | |
| Xie Jian | FLGT | President and COO | Sep 3 '24 | Sell | $21.96 | 1,594 | $35,005.83 | 341,170 | |
| Kim Paul | FLGT | CFO and Treasurer | Sep 3 '24 | Sell | $21.96 | 1,674 | $36,762.71 | 209,481 | |
| Hsieh Ming | FLGT | Chief Executive Officer | Aug 27 '24 | Sell | $22.83 | 2,313 | $52,812.73 | 707,275 | |
| Gao Hanlin | FLGT | Chief Scientific Officer | Aug 27 '24 | Sell | $22.83 | 563 | $12,854.98 | 923,057 | |
| Xie Jian | FLGT | President and COO | Aug 27 '24 | Sell | $22.83 | 715 | $16,325.60 | 341,170 | |
| Kim Paul | FLGT | CFO and Treasurer | Aug 27 '24 | Sell | $22.83 | 733 | $16,736.59 | 209,481 |
Latest Fulgent Genetics Inc. News
FLGT Breaking Stock News: Dive into FLGT Ticker-Specific Updates for Smart Investing
Insider Monkey
2 days ago
Fulgent Genetics, Inc. (FLGT): Among the Best Genomics Stocks to Buy Right Now
Argus Research
9 days ago
FLGT: Lowering target price to $20.00
Simply Wall St.
11 days ago
Companies Like Fulgent Genetics (NASDAQ:FLGT) Are In A Position To Invest In Growth
Simply Wall St.
11 days ago
Fulgent Genetics Third Quarter 2024 Earnings: EPS Misses Expectations
TipRanks
12 days ago
Fulgent Genetics Reports Strong Q3 2024 Results
GuruFocus.com
12 days ago
Fulgent Genetics Inc (FLGT) Q3 2024 Earnings Call Highlights: Strategic Growth Amid Revenue Decline
Zacks
13 days ago
Fulgent Genetics, Inc. (FLGT) Surpasses Q3 Earnings and Revenue Estimates
Business Wire
13 days ago
Fulgent Reports Third Quarter 2024 Financial Results
Compare FLGT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "FLGT Fulgent Genetics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.